nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadodiamide—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Gadodiamide—Abdominal pain—Captopril—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Gadodiamide—Body temperature increased—Captopril—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Gadodiamide—Oedema—Mycophenolic acid—systemic scleroderma	0.00175	0.00175	CcSEcCtD
Gadodiamide—Nausea—Pentoxifylline—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Gadodiamide—Chills—Mycophenolate mofetil—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Gadodiamide—Malaise—Lisinopril—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Gadodiamide—Infection—Mycophenolic acid—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Gadodiamide—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Gadodiamide—Diarrhoea—Mometasone—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Gadodiamide—Syncope—Lisinopril—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Gadodiamide—Renal failure acute—Methotrexate—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Gadodiamide—Shock—Mycophenolic acid—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Gadodiamide—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Gadodiamide—Hypotension—Leflunomide—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Gadodiamide—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Gadodiamide—Loss of consciousness—Lisinopril—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Gadodiamide—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Gadodiamide—Visual disturbance—Methotrexate—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Gadodiamide—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Gadodiamide—Paraesthesia—Leflunomide—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Gadodiamide—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Gadodiamide—Myalgia—Lisinopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Gadodiamide—Chest pain—Lisinopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Gadodiamide—Arthralgia—Lisinopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Gadodiamide—Anxiety—Lisinopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Gadodiamide—Dyspnoea—Leflunomide—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Gadodiamide—Hypotension—Mycophenolic acid—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Gadodiamide—Discomfort—Lisinopril—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Gadodiamide—Dyspepsia—Leflunomide—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Gadodiamide—Vomiting—Mometasone—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Gadodiamide—Dry mouth—Lisinopril—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Gadodiamide—Sweating increased—Prednisone—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Gadodiamide—Feeling abnormal—Azathioprine—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Gadodiamide—Rash—Mometasone—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Gadodiamide—Asthenia—Captopril—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Gadodiamide—Dermatitis—Mometasone—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Gadodiamide—Headache—Mometasone—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Gadodiamide—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Gadodiamide—Fatigue—Leflunomide—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Gadodiamide—Oedema—Lisinopril—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Gadodiamide—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Gadodiamide—Pruritus—Captopril—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Gadodiamide—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Gadodiamide—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Gadodiamide—Pain—Leflunomide—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Gadodiamide—Infection—Lisinopril—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Gadodiamide—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Gadodiamide—Somnolence—Mycophenolic acid—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Gadodiamide—Shock—Lisinopril—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Gadodiamide—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Gadodiamide—Tachycardia—Lisinopril—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Gadodiamide—Abdominal pain—Azathioprine—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Gadodiamide—Body temperature increased—Azathioprine—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Gadodiamide—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Gadodiamide—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Gadodiamide—Diarrhoea—Captopril—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Gadodiamide—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Gadodiamide—Feeling abnormal—Leflunomide—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Gadodiamide—Fatigue—Mycophenolic acid—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Gadodiamide—Nausea—Mometasone—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Gadodiamide—Ataxia—Methotrexate—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Gadodiamide—Pain—Mycophenolic acid—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Gadodiamide—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Gadodiamide—Hypotension—Lisinopril—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Gadodiamide—Dizziness—Captopril—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Gadodiamide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Gadodiamide—Urticaria—Leflunomide—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Gadodiamide—Abdominal pain—Leflunomide—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Gadodiamide—Body temperature increased—Leflunomide—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Gadodiamide—Acute coronary syndrome—Prednisone—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Gadodiamide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Gadodiamide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Gadodiamide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Gadodiamide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Gadodiamide—Myocardial infarction—Prednisone—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Gadodiamide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Gadodiamide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Gadodiamide—Hypersensitivity—Azathioprine—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Gadodiamide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Gadodiamide—Paraesthesia—Lisinopril—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Gadodiamide—Vomiting—Captopril—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Gadodiamide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Gadodiamide—Dyspnoea—Lisinopril—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Gadodiamide—Rash—Captopril—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Gadodiamide—Dermatitis—Captopril—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Gadodiamide—Somnolence—Lisinopril—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Gadodiamide—Headache—Captopril—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Gadodiamide—Dyspepsia—Lisinopril—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Gadodiamide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Gadodiamide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Gadodiamide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Gadodiamide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Gadodiamide—Infection—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Gadodiamide—Fatigue—Lisinopril—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Gadodiamide—Shock—Mycophenolate mofetil—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Gadodiamide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Gadodiamide—Hypersensitivity—Leflunomide—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Gadodiamide—Pain—Lisinopril—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Gadodiamide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Gadodiamide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Gadodiamide—Diarrhoea—Azathioprine—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Gadodiamide—Nausea—Captopril—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Gadodiamide—Asthenia—Leflunomide—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Gadodiamide—Hallucination—Prednisone—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Gadodiamide—Feeling abnormal—Lisinopril—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Gadodiamide—Pruritus—Leflunomide—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Gadodiamide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Gadodiamide—Dizziness—Azathioprine—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Gadodiamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Gadodiamide—Diarrhoea—Leflunomide—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Gadodiamide—Urticaria—Lisinopril—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Gadodiamide—Body temperature increased—Lisinopril—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Gadodiamide—Abdominal pain—Lisinopril—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Gadodiamide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Gadodiamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Gadodiamide—Vomiting—Azathioprine—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Gadodiamide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Gadodiamide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Gadodiamide—Rash—Azathioprine—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Gadodiamide—Dermatitis—Azathioprine—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Gadodiamide—Flushing—Prednisone—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Gadodiamide—Headache—Azathioprine—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Gadodiamide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Gadodiamide—Dizziness—Leflunomide—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Gadodiamide—Renal failure—Methotrexate—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Gadodiamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Gadodiamide—Pain—Mycophenolate mofetil—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Gadodiamide—Arrhythmia—Prednisone—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Gadodiamide—Vomiting—Leflunomide—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Gadodiamide—Hypersensitivity—Lisinopril—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Gadodiamide—Dizziness—Mycophenolic acid—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Gadodiamide—Rash—Leflunomide—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Gadodiamide—Dermatitis—Leflunomide—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Gadodiamide—Nausea—Azathioprine—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Gadodiamide—Headache—Leflunomide—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Gadodiamide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Gadodiamide—Asthenia—Lisinopril—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Gadodiamide—Pruritus—Lisinopril—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Gadodiamide—Vomiting—Mycophenolic acid—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Gadodiamide—Rash—Mycophenolic acid—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Gadodiamide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Gadodiamide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Gadodiamide—Headache—Mycophenolic acid—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Gadodiamide—Pharyngitis—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Gadodiamide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Gadodiamide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Gadodiamide—Nausea—Leflunomide—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Gadodiamide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Gadodiamide—Urethral disorder—Methotrexate—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Gadodiamide—Diarrhoea—Lisinopril—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Gadodiamide—Ill-defined disorder—Prednisone—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Gadodiamide—Visual impairment—Methotrexate—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Gadodiamide—Dizziness—Lisinopril—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Gadodiamide—Nausea—Mycophenolic acid—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Gadodiamide—Malaise—Prednisone—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Gadodiamide—Syncope—Prednisone—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Gadodiamide—Tinnitus—Methotrexate—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Gadodiamide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Gadodiamide—Loss of consciousness—Prednisone—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Gadodiamide—Vomiting—Lisinopril—systemic scleroderma	0.001	0.001	CcSEcCtD
Gadodiamide—Rash—Lisinopril—systemic scleroderma	0.000994	0.000994	CcSEcCtD
Gadodiamide—Convulsion—Prednisone—systemic scleroderma	0.000994	0.000994	CcSEcCtD
Gadodiamide—Dermatitis—Lisinopril—systemic scleroderma	0.000993	0.000993	CcSEcCtD
Gadodiamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000991	0.000991	CcSEcCtD
Gadodiamide—Chills—Methotrexate—systemic scleroderma	0.000988	0.000988	CcSEcCtD
Gadodiamide—Headache—Lisinopril—systemic scleroderma	0.000987	0.000987	CcSEcCtD
Gadodiamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000977	0.000977	CcSEcCtD
Gadodiamide—Arthralgia—Prednisone—systemic scleroderma	0.000976	0.000976	CcSEcCtD
Gadodiamide—Myalgia—Prednisone—systemic scleroderma	0.000976	0.000976	CcSEcCtD
Gadodiamide—Anxiety—Prednisone—systemic scleroderma	0.000973	0.000973	CcSEcCtD
Gadodiamide—Discomfort—Prednisone—systemic scleroderma	0.000965	0.000965	CcSEcCtD
Gadodiamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000945	0.000945	CcSEcCtD
Gadodiamide—Dysgeusia—Methotrexate—systemic scleroderma	0.000938	0.000938	CcSEcCtD
Gadodiamide—Nausea—Lisinopril—systemic scleroderma	0.000936	0.000936	CcSEcCtD
Gadodiamide—Oedema—Prednisone—systemic scleroderma	0.000936	0.000936	CcSEcCtD
Gadodiamide—Anaphylactic shock—Prednisone—systemic scleroderma	0.000936	0.000936	CcSEcCtD
Gadodiamide—Infection—Prednisone—systemic scleroderma	0.00093	0.00093	CcSEcCtD
Gadodiamide—Shock—Prednisone—systemic scleroderma	0.000921	0.000921	CcSEcCtD
Gadodiamide—Nervous system disorder—Prednisone—systemic scleroderma	0.000918	0.000918	CcSEcCtD
Gadodiamide—Tachycardia—Prednisone—systemic scleroderma	0.000913	0.000913	CcSEcCtD
Gadodiamide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000913	0.000913	CcSEcCtD
Gadodiamide—Hyperhidrosis—Prednisone—systemic scleroderma	0.000905	0.000905	CcSEcCtD
Gadodiamide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000889	0.000889	CcSEcCtD
Gadodiamide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000878	0.000878	CcSEcCtD
Gadodiamide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000871	0.000871	CcSEcCtD
Gadodiamide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00087	0.00087	CcSEcCtD
Gadodiamide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000865	0.000865	CcSEcCtD
Gadodiamide—Malaise—Methotrexate—systemic scleroderma	0.000864	0.000864	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000853	0.000853	CcSEcCtD
Gadodiamide—Paraesthesia—Prednisone—systemic scleroderma	0.00084	0.00084	CcSEcCtD
Gadodiamide—Convulsion—Methotrexate—systemic scleroderma	0.00083	0.00083	CcSEcCtD
Gadodiamide—Dyspepsia—Prednisone—systemic scleroderma	0.000824	0.000824	CcSEcCtD
Gadodiamide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00082	0.00082	CcSEcCtD
Gadodiamide—Chest pain—Methotrexate—systemic scleroderma	0.000816	0.000816	CcSEcCtD
Gadodiamide—Arthralgia—Methotrexate—systemic scleroderma	0.000816	0.000816	CcSEcCtD
Gadodiamide—Myalgia—Methotrexate—systemic scleroderma	0.000816	0.000816	CcSEcCtD
Gadodiamide—Fatigue—Prednisone—systemic scleroderma	0.000807	0.000807	CcSEcCtD
Gadodiamide—Discomfort—Methotrexate—systemic scleroderma	0.000806	0.000806	CcSEcCtD
Gadodiamide—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000782	0.000782	CcSEcCtD
Gadodiamide—Infection—Methotrexate—systemic scleroderma	0.000777	0.000777	CcSEcCtD
Gadodiamide—Feeling abnormal—Prednisone—systemic scleroderma	0.000771	0.000771	CcSEcCtD
Gadodiamide—Nervous system disorder—Methotrexate—systemic scleroderma	0.000767	0.000767	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000765	0.000765	CcSEcCtD
Gadodiamide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000756	0.000756	CcSEcCtD
Gadodiamide—Urticaria—Prednisone—systemic scleroderma	0.000743	0.000743	CcSEcCtD
Gadodiamide—Abdominal pain—Prednisone—systemic scleroderma	0.00074	0.00074	CcSEcCtD
Gadodiamide—Body temperature increased—Prednisone—systemic scleroderma	0.00074	0.00074	CcSEcCtD
Gadodiamide—Hypotension—Methotrexate—systemic scleroderma	0.000731	0.000731	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000713	0.000713	CcSEcCtD
Gadodiamide—Paraesthesia—Methotrexate—systemic scleroderma	0.000702	0.000702	CcSEcCtD
Gadodiamide—Dyspnoea—Methotrexate—systemic scleroderma	0.000697	0.000697	CcSEcCtD
Gadodiamide—Somnolence—Methotrexate—systemic scleroderma	0.000695	0.000695	CcSEcCtD
Gadodiamide—Hypersensitivity—Prednisone—systemic scleroderma	0.00069	0.00069	CcSEcCtD
Gadodiamide—Dyspepsia—Methotrexate—systemic scleroderma	0.000688	0.000688	CcSEcCtD
Gadodiamide—Fatigue—Methotrexate—systemic scleroderma	0.000674	0.000674	CcSEcCtD
Gadodiamide—Asthenia—Prednisone—systemic scleroderma	0.000671	0.000671	CcSEcCtD
Gadodiamide—Pain—Methotrexate—systemic scleroderma	0.000669	0.000669	CcSEcCtD
Gadodiamide—Pruritus—Prednisone—systemic scleroderma	0.000662	0.000662	CcSEcCtD
Gadodiamide—Feeling abnormal—Methotrexate—systemic scleroderma	0.000645	0.000645	CcSEcCtD
Gadodiamide—Diarrhoea—Prednisone—systemic scleroderma	0.00064	0.00064	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00064	0.00064	CcSEcCtD
Gadodiamide—Urticaria—Methotrexate—systemic scleroderma	0.000621	0.000621	CcSEcCtD
Gadodiamide—Dizziness—Prednisone—systemic scleroderma	0.000619	0.000619	CcSEcCtD
Gadodiamide—Body temperature increased—Methotrexate—systemic scleroderma	0.000618	0.000618	CcSEcCtD
Gadodiamide—Abdominal pain—Methotrexate—systemic scleroderma	0.000618	0.000618	CcSEcCtD
Gadodiamide—Vomiting—Prednisone—systemic scleroderma	0.000595	0.000595	CcSEcCtD
Gadodiamide—Rash—Prednisone—systemic scleroderma	0.00059	0.00059	CcSEcCtD
Gadodiamide—Dermatitis—Prednisone—systemic scleroderma	0.00059	0.00059	CcSEcCtD
Gadodiamide—Headache—Prednisone—systemic scleroderma	0.000586	0.000586	CcSEcCtD
Gadodiamide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000576	0.000576	CcSEcCtD
Gadodiamide—Asthenia—Methotrexate—systemic scleroderma	0.000561	0.000561	CcSEcCtD
Gadodiamide—Nausea—Prednisone—systemic scleroderma	0.000556	0.000556	CcSEcCtD
Gadodiamide—Pruritus—Methotrexate—systemic scleroderma	0.000553	0.000553	CcSEcCtD
Gadodiamide—Diarrhoea—Methotrexate—systemic scleroderma	0.000535	0.000535	CcSEcCtD
Gadodiamide—Dizziness—Methotrexate—systemic scleroderma	0.000517	0.000517	CcSEcCtD
Gadodiamide—Vomiting—Methotrexate—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Gadodiamide—Rash—Methotrexate—systemic scleroderma	0.000493	0.000493	CcSEcCtD
Gadodiamide—Dermatitis—Methotrexate—systemic scleroderma	0.000493	0.000493	CcSEcCtD
Gadodiamide—Headache—Methotrexate—systemic scleroderma	0.00049	0.00049	CcSEcCtD
Gadodiamide—Nausea—Methotrexate—systemic scleroderma	0.000465	0.000465	CcSEcCtD
